In a bold move aimed at reducing healthcare costs, former President Donald Trump has issued an executive order directing his health department to collaborate with Congress on overhauling the law that governs Medicare's ability to negotiate prescription drug prices. The pharmaceutical industry has been lobbying for changes that would delay the eligibility of small molecule drugs for price negotiations, aligning them with the timeline for more complex biotech drugs.
Under President Joe Biden's Inflation Reduction Act, Medicare was granted the authority to negotiate prices for selected medications, a measure that has raised concerns among drugmakers regarding potential stifling of innovation. With the current law allowing negotiations for biologic drugs after 13 years on the market and for pills and capsules after 9 years, Trump's order seeks to address these issues by pushing for reform with the assistance of Health and Human Services Secretary Robert F. Kennedy Jr.
The Trump administration's executive order also includes provisions to align Medicare payments for drugs with hospital rates, standardize patient payment rates across locations, and streamline FDA approval processes for generic and biosimilar medications. These initiatives are set to bring about significant changes in the pharmaceutical industry and healthcare sector as a whole.
Furthermore, Trump's directive to encourage more states to apply for drug importation programs aims to increase access to affordable medications for consumers. Although progress has been made with Florida receiving FDA authorization to import drugs from Canada, Trump seeks to expand these efforts to benefit more states and ultimately drive competition and cost savings in the drug market.